T-DXd is recommended by the 2023 National Comprehensive Cancer Network (NCCN) gastric cancer guidelines as a second-line or subsequent treatment option for patients with HER2 overexpression–positive adenocarcinoma following failure of prior treatment with a trastuzumab-based regimen [12]. This evidence concerns the gene ERBB2 and gastric cancer.